The MFSD4B Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the MFSD4B gene. This gene-edited product is generated by CRISPR/Cas9-mediated disruption of the target locus in the Raji B lymphocyte cell line, yielding a mixed population of cells with heterogeneous gene-editing events. The polyclonal format provides a robust model for investigating the functional consequences of MFSD4B inactivation without the clonal selection biases inherent in single-cell-derived lines. Researchers can use these cells to probe the role of MFSD4B in membrane transport processes and its impact on lymphocyte biology.
The parental Raji cell line is a well-established human B lymphoblastoid line originally derived from a Nigerian patient with Epstein-Barr virus (EBV)-positive Burkitt lymphoma. Raji cells exhibit characteristics of mature B lymphocytes and are extensively utilized in immunological and oncological research due to their capacity for antibody production, antigen presentation, and cytokine secretion. These cells express cell surface markers typical of the B-cell lineage and have been instrumental in elucidating mechanisms of lymphomagenesis, viral latency, and immune evasion. The EBV-positive status of Raji cells provides a context-specific advantage for studying viral-host interactions and lymphoproliferative pathways in a B-cell malignancy setting.
MFSD4B encodes a putative protein of the major facilitator superfamily (MFS), a large and diverse group of evolutionarily related membrane transporters. MFS proteins typically function as solute carriers, facilitating the movement of small molecules such as ions, sugars, and metabolites across cellular membranes. Although the exact substrate specificity and transport mechanism of MFSD4B remain uncharacterized, it is predicted to participate in solute carrier-mediated transport pathways. The signaling network directly involving MFSD4B is not well defined, as upstream regulators, downstream targets, and interacting factors have yet to be identified. However, MFSD4B is conceptually linked to broader transport systems that include related MFS and SLC family transporters, which play critical roles in cellular homeostasis and drug disposition.
In the context of Raji Burkitt lymphoma cells, disruption of MFSD4B offers a powerful tool to dissect the contribution of membrane transport to cancer cell biology and therapeutic response. Given the potential involvement of MFSD4B in drug resistance, this knockout model is particularly relevant for screening chemosensitivity and exploring mechanisms by which B-lymphoma cells evade cytotoxic agents. The interplay between transport activity and essential lymphocyte functions??such as antigen presentation and cytokine secretion??may also be investigated, providing insights into how metabolic and transport adaptations support malignant progression. Moreover, the polyclonal nature of the knockout population allows for assessment of phenotypic heterogeneity in transport-dependent processes within a lymphomagenic background.
These MFSD4B knockout Raji polyclonal cells are ideally suited for a range of experimental applications in transporter biology and oncology. Functional analyses can employ fluorescent substrate uptake assays to monitor transporter activity, while cell viability assays such as MTT or ATP-based tests enable drug sensitivity profiling. Researchers can combine these phenotypic readouts with molecular techniques including western blotting, RT-qPCR, and flow cytometry to assess protein and gene expression changes. High-throughput approaches like RNA-seq transcriptomics further allow global transcriptome profiling to uncover downstream effects of MFSD4B disruption. This model thus supports comprehensive studies of transport-dependent processes in B-cell lymphoma. For further information or technical support, please contact Ascent Research.
